Literature DB >> 27821613

Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada.

M Eugenia Socías1,2, Putu Duff1, Jean Shoveller1,3, Julio S G Montaner1,2, Paul Nguyen1, Gina Ogilvie3, Kate Shannon1,2,3.   

Abstract

OBJECTIVES: Increased risk of herpes simplex virus 2 (HSV-2) has been proposed as a possible indirect pathway through which hormonal contraceptives (specifically depot medroxyprogesterone acetate (DMPA)) may increase the risk of HIV acquisition among women. We investigated the effects of DMPA on HSV-2 acquisition among female sex workers.
METHODS: Longitudinal data were drawn from a prospective cohort of sex workers in Vancouver, Canada. The primary outcome was HSV-2 seroconversion. Extended Cox regression analyses were used to model the independent effect of DMPA use on HSV-2 acquisition.
RESULTS: Between January 2010 and February 2014, 149 HSV-2 seronegative women were enrolled, contributing to 228 person-years (py) of follow-up. Of these, 19 (13.3%) reported DMPA use. There were 39 HSV-2 seroconversions (12 among DMPA users and 27 among non-users) over the study period (median follow-up of 18.6 months (IQR 8.4-29.9)), resulting in an overall incidence rate of 17.1 cases per 100 py (95% CI 12.4 to 23.6). Incidence rates were higher among DMPA users (57.4 cases per 100 py, 95% CI 31.4 to 105.0) compared with non-users (13.1 cases per 100 py, 95% CI 8.9 to 19.1). After adjusting for key confounders, use of DMPA remained an independent predictor of HSV-2 acquisition (adjusted HR 4.43, 95% CI 1.90 to 10.35).
CONCLUSIONS: The high observed incidence rates of HSV-2, together with a strong association between DMPA exposure and HSV-2 acquisition, raise serious concerns about the provision of optimal reproductive and sexual healthcare to sex workers in this setting. Given the known links between HSV-2 and HIV, our findings underscore the need for further research to better understand the potential association between DMPA and increased risk of HSV-2 and other STIs to help inform the development of safer reproductive choices for women worldwide. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  HIV; HORMONAL CONTRACEPTION; HSV

Mesh:

Substances:

Year:  2016        PMID: 27821613      PMCID: PMC5420492          DOI: 10.1136/sextrans-2016-052838

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  26 in total

Review 1.  Contraceptive methods and risk of HIV acquisition or female-to-male transmission.

Authors:  Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

2.  Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.

Authors:  J M Baeten; P M Nyange; B A Richardson; L Lavreys; B Chohan; H L Martin; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss
Journal:  Am J Obstet Gynecol       Date:  2001-08       Impact factor: 8.661

3.  Progesterone increases susceptibility and decreases immune responses to genital herpes infection.

Authors:  Charu Kaushic; Ali A Ashkar; Lesley A Reid; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Authors:  Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum
Journal:  Lancet       Date:  2010-02-12       Impact factor: 79.321

5.  Evaluation of a novel serology algorithm to detect herpes simplex virus 1 or 2 antibodies.

Authors:  George Zahariadis; Alberto Severini
Journal:  Sex Transm Dis       Date:  2010-11       Impact factor: 2.830

6.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

7.  A pooled analysis of the effect of condoms in preventing HSV-2 acquisition.

Authors:  Emily T Martin; Elizabeth Krantz; Sami L Gottlieb; Amalia S Magaret; Andria Langenberg; Lawrence Stanberry; Mary Kamb; Anna Wald
Journal:  Arch Intern Med       Date:  2009-07-13

Review 8.  Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception.

Authors:  P D Blumenthal; A Voedisch; K Gemzell-Danielsson
Journal:  Hum Reprod Update       Date:  2010-07-15       Impact factor: 15.610

Review 9.  Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

Authors:  Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

Review 10.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  5 in total

1.  The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions.

Authors:  Elizabeth Micks; Hyunju Son; Amalia Magaret; Stacy Selke; Christine Johnston; Anna Wald
Journal:  Sex Transm Dis       Date:  2019-01       Impact factor: 2.830

2.  Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).

Authors:  G Justus Hofmeyr; Charles S Morrison; Jared M Baeten; Tsungai Chipato; Deborah Donnell; Peter Gichangi; Nelly Mugo; Kavita Nanda; Helen Rees; Petrus Steyn; Douglas Taylor
Journal:  Gates Open Res       Date:  2018-03-13

Review 3.  Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives.

Authors:  Jennifer Deese; Subarna Pradhan; Hannah Goetz; Charles Morrison
Journal:  Open Access J Contracept       Date:  2018-11-12

4.  Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro.

Authors:  Mickey V Patel; Marta Rodriguez-Garcia; Zheng Shen; Charles R Wira
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

5.  Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.

Authors:  Nelly R Mugo; Randy M Stalter; Renee Heffron; Helen Rees; Caitlin W Scoville; Charles Morrison; Athena P Kourtis; Elizabeth Bukusi; Mags Beksinka; Neena M Philip; Ivana Beesham; Jen Deese; Vinodh Edward; Deborah Donnell; Jared M Baeten
Journal:  Clin Infect Dis       Date:  2022-09-10       Impact factor: 20.999

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.